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Multiple system atrophy (MSA) clinically is characterized by prominent autonomic dysfunction 
with combinations of parkinsonian features (MSA-P), cerebellar ataxia (MSA-C) and possible 
corticospinal symptoms. Autonomic dysfunction in MSA comprises cardinal symptoms of 
orthostatic hypotension (OH) and urinary incontinence. Additionally, sudomotor and cardiovagal 
abnormalities are frequently present among the MSA patients. 
Due to overlapping motor presentations it can be very challenging to distinguish MSA-P from 
Parkinson's disease (PD). The cardinal MSA autonomic symptoms - OH and urinary 
incontinence - are of limited assistance while these symptoms are common among the PD 
patients as well. Autonomic abnormalities for the PD patients may also include constipation, heat 
or cold intolerance, postprandial hypotension and relative nocturnal hypertension.
Previous studies compared hand skin temperature and its response to cooling in subjects with PD 
and probable MSA. Significant differences regarding hand temperature before and after cooling, 
as well as kinetics of natural rewarming were found indicating that disturbed neurovascular 
thermoregulation of distal extremities potentially belongs to MSA autonomic features and could 
be helpful in clinical differentiation of MSA-P from PD. Up to the present, however, only a 
minor study sample has been reported. 
In this study we sought to improve our knowledge about impaired thermoregulation of distal 
extremities in patients suffering from MSA and PD. Furthermore, the coexistence and possible 
interrelations for the different subtypes of autonomic dysfunction were assessed in a large cohort 
of MSA, PD and control patients. 
In the study 112 MSA, 500 PD and 129 control patients underwent a standard cooling -
rewarming procedure, termed ice test (IT). Additionally the subdivision of the patients received 
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peripheral and autonomic nervous systems clinically evaluated. The evaluation included 
electroneurography and autonomic function tests of heart rate variability, sympathetic skin 
response and lying-to-standing orthostatic test.
The results of this study indicate that the prevalence of pathological IT, the frequencies of 
gradually increasing temperature decrement and the mean temperature decrement in pathological
IT were higher in the MSA group compared with the PD and the control groups, the differences 
were insufficient for statistical significance. The presence of pathological IT was significantly 
associated with older patient's age in the PD and the control study groups (p < 0.05). This 
association was absent for the MSA patients, who themselves were significantly younger (p = 
0.001). Significant correlation between the presence of pathological IT and the autonomic 
symptom of OH was determined (p < 0.001).
To conclude, defective thermoregulation of distal extremities is potentially more severe in the 
MSA patients. So-called ice test however does not differentiate MSA-P and PD reliably. The 
dysfunction of preganglionic sympathetic neurons might be involved in impaired response to 
cooling for MSA. The results suggest a pathophysiological affinity between pathological IT and 
OH, which could be defective sympathetic neurovascular regulation. Specific autonomic testing 
including IT may help in the differentiation of MSA-P and PD.
I. INTRODUCTION
1. Multiple System Atrophy
1.1. Clinical Presentation 
Multiple system atrophy (MSA) is a sporadic, adult-onset and relatively rapidly progressive 
neurodegenerative disorder. MSA clinically is characterized by prominent autonomic 
dysfunction with combinations of parkinsonian features (MSA-P), cerebellar ataxia (MSA-C) 
and possible corticospinal symptoms [1].
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MSA-P is determined in 60% of patients in the western hemisphere, whereas MSA-C constitutes 
40% of patients. The approximately reverse distribution is observed in the eastern hemisphere [2, 
3].
Parkinsonism in MSA-P is characterized by progressive akinesia and rigidity. The motor 
findings are sometimes asymmetrical. Resting tremor is less common than in Parkinson‘s disease
(PD). However irregular postural and action tremor with superimposed jerks can be seen in as 
many as 50% of patients with MSA [4]. Postural stability is impaired early after the onset of 
disease. Recurrent falls at disease onset are however rather unusual in MSA. Progressive 
degeneration of the striatum accounts for the poor response or lack of response to levodopa. 
Nevertheless, a transient response to levodopa may be observed in approximately 40% of 
patients during early disease stages [5]. This is sometimes accompanied by drug-induced 
involuntary movements, such as head–neck dystonia, an involuntary muscle contraction resulting 
in abnormal twisting postures [6].
The cerebellar disorder of MSA-C is composed of gait ataxia, limb kinetic ataxia, and scanning 
dysarthria, as well as cerebellar oculomotor disturbances. Spontaneous, gaze-evoked, or 
positional downbeat nystagmus may be present. 
Generalized hyperreflexia with or without a Babinski sign, may occur in 30 to 50% of cases [4].
In addition, features of abnormal spine posture (camptocormia), disproportionate antecollis, 
severe lateral flexion of the spine (Pisa syndrome) and hand or foot dystonia are associated with 
the motor presentation of MSA in 16 to 42% of patients [7]. Dysphonia, dysarthria, drooling 
(saliva loss) and dysphagia are defining symptoms of advanced stage disease [1].
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Autonomic failure develops in almost all patients with MSA [8]. Early impotence is typical in 
men. Urinary incontinence or incomplete bladder emptying, often early after the disease onset or 
even as a presenting symptom, are frequent. Orthostatic hypotension (OH) is present in 
approximately 70% of MSA patients being main feature of cardiovascular autonomic failure in 
clinically established MSA [4]. Symptoms of OH include lightheadedness, dizziness, postural 
instability, vertigo and blurred vision. OH can manifest as recurrent syncope, but it may also be 
asymptomatic. When associated with clinical symptoms OH indicates a decrease in cerebral 
perfusion. Falls with injuries may also result. OH often deteriorates the general condition of 
MSA patients and may contribute to morbidity, disability and even death, because of the 
potential risk of substantial injury [9, 10]. Postprandial hypotension and supine and nocturnal
hypertension accompany orthostatic hypotension in half of patients with MSA [11]. Respiratory 
problems are common in MSA. Inspiratory stridor develops in nearly 50% of patients at some 
time. It is more frequent in advanced disease [7].
Other autonomic disturbances in MSA include constipation [12], pupillomotor abnormalities, 
vasomotor failure with diminished sweating [13, 14] and disturbed neurovascular 
thermoregulation of distal extremities [15] with a possible cold hand sign [14].
1.2. Historical Approach
The concept of MSA as a unifying entity comprising several clinical syndromes has a long 
history. The first cases of MSA were presented as olivopontocerebellar atrophy in 1900. The 
Shy-Drager syndrome with autonomic failure including OH and striatonigral degeneration 
featuring parkinsonism was described in 1960. These cardinal presentations of MSA -
striatonigral degeneration, olivopontocerebellar atrophy and Shy–Drager syndrome - were 
regarded as distinct entities until Graham and Oppenheimer recognized their substantial 
clinicopathological overlap and proposed MSA as an umbrella term in 1969 [16]. 
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Ubiquitinpositive glial cytoplasmic inclusions (GCI) were first reported in 1989 [17] and 
subsequently confirmed as a cellular marker of MSA regardless of the phenotypic presentation. 
Alpha-synuclein immunostaining of GCI was first described in 1998. Following this discovery, 
MSA has been regarded as α-synucleinopathy along with PD, Lewy body dementia, and pure 
autonomic failure. Quinn proposed the first set of diagnostic criteria and distinguished the motor 
subtypes MSA-P and MSA-C, although there was unintended overlap. A consensus conference 
was convened in 1998 that proposed clinical guidelines exclusively for the diagnosis of MSA. 
The latter was divided into MSA-P and MSA-C depending on the dominant motor presentation 
at the time of examination [18]. Based on improvements of early diagnosis by defining warning 
signs and sensitive neuroimaging indices, the consensus guidelines were revised in 2008 [19]. A 
Unified MSA Rating Scale quantifying disease severity has been established and validated in the 
meantime by the European MSA Study Group [20]. Animal models have become available as 
preclinical test beds for translational neuroprotection and neuroregeneration studies [21]. The 
first clinical trials have been conducted by two independent consortia using minocycline [22] and 
riluzole [23]. Other international networks have been established in the last few years including 
North American MSA Study Group [24], Japanese MSA Consortium, and Chinese MSA Study 
Group. Globalization of MSA research has led not only to the clinical trials, mentioned above, 
but also to the first genetic breakthrough by identifying variants in the α-synuclein gene and their 
association with increased disease risk in a large population of MSA patients [25].
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Table I. Timeline for definitions of MSA.
Definition Time Authors Subject
Olivopontocerebellar 
atrophy (OPCA)
1900 Dejerine and 
Thomas
Introduction of the term 
olivopontocerebellar atrophy
Orthostatic hypotension 1925 Bradbury and 
Eggleston




1960 Shy and Drager Origin of this term as a neuropathologic 




1960 Van der Eecken et 
al
Description of SND
Multiple system atrophy 1969 Graham and 
Oppenheimer
Introduction of the term MSA, which 




1989 Papp et al, Matsuo 
et al
Discovery of GCI as hallmark of MSA
Alpha-synuclein inclusion 1998 Spillantini et al, 
Wakabayashi et al
Alpha-synuclein immunostaining as a 





Classification of MSA based on clinical 
domains and features and neuropathology
Unified MSA Rating 
Scale (UMSARS)
2003 European MSA 
Study Group
Unified MSA Rating Scale as a standard 
to define MSA symptoms




New definition of MSA with simplified 
criteria
1.3. Epidemiologic Features
The estimated prevalence of MSA is reported to be between 3.4-4.9 cases per 100000 of 
population. The estimated mean incidence is 0.6-0.7 cases per 100000 persons per year. Hence 
MSA meets orphan disease status [26, 27]. The reported prevalence increases to 7.8 per 100000 
among persons older than 40 years of age [28]. Regional reports on the MSA occurrence state, 
that in the European Union the prevalence reaches 4-5 cases per 100000 persons. The incidence 
rate is about 0.6 cases per 100000 persons per year [28]. In the United Kingdom the overall 
prevalence of MSA, including all probable and possible cases, is 3.3 per 100000 of population 
[4]. In Iceland the annual incidence is 0.6 per 100000 and prevalence is 3.1 per 100000 [4]. In 
Japan the prevalence is 13.1 per 100000 individuals [2]. The mean annual incidence is 0.68 [3].
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1.4. Etiology and Neuropathophysiology
We lack a complete understanding of the etiopathologic factors for MSA. Similar to other 
sporadic neurodegenerative diseases, a complex interaction of genetic and environmental 
mechanisms seems very likely [29]. Mercury, methanol, carbon tetrachloride, carbon disulfide 
and cyanide have been associated with MSA-like parkinsonism in a small series of cases [30]. 
Manganese intoxication reported in miners can produce clinical, neuroimaging, and pathological 
findings that may overlap with those of MSA [30]. The few controlled studies available in the 
literature have attempted to associate the increased risk of MSA with occupational and daily 
habits like farming using pesticides, working exposure to solvents, plastic monomers, additives 
and metals [31, 32, 33]. However, the increased risk of MSA related to occupational toxins has 
not been confirmed by any previous study [34].  Nicotine use and alcohol consumption are less 
common among the MSA patients than in healthy controls [1].
MSA is considered to be a sporadic disease. Nevertheless, rare familial cases have been reported 
indicating that genetic factors have an etiologic role in some families [35, 36]. In a few European 
and Japanese pedigrees, MSA has been transmitted in an autosomal dominant or recessive 
inheritance pattern [37, 38]. In addition, some studies suggest that spinocerebellar ataxia type 1 
and other forms of spinocerebellar ataxias as well as fragile X–associated tremor/ataxia 
syndrome might be associated with MSA-like presentations [39, 40, 41, 42]. Mutations, 
duplications, and triplications of α-synuclein gene SNCA may cause familial PD with 
characteristics similar to MSA in some affected persons [43]. Two single-nucleotide 
polymorphisms of the SNCA locus showed a significant association with MSA in a large series 
of European patients [25]. This association was confirmed in follow-up replication studies [44],
but not in the preliminary analysis of the first genome-wide association study of MSA [45, 46].
Genes coding for apolipoprotein E, dopamine β-hydroxylase, ubiquitin C-terminal hydrolase-1, 
fragile X mental retardation 1, and leucine-rich kinase 2 showed no association with MSA [47]. 
In contrast, polymorphisms of several genes involved in inflammatory processes have been 
associated with an elevated MSA risk. These include genes coding for interleukin-1A, 
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interleukin-1B, interleukin-8, intercellular adhesion molecule-1 and tumor necrosis factor, and 
alpha-1-antichymotrypsin [48, 49, 50, 51, 52]. Homozygosity for interleukin-1A allele 2 
increases the risk to develop MSA as much as five-fold. The alpha-1-antichymotrypsin AA 
genotype is associated with a significantly earlier onset and faster disease progression [51]. A 
previous study showed that MSA is also associated with polymorphisms of genes involved in 
oxidative stress [53].
MSA is regarded as an oligodendroglial α-synucleinopathy. Other known α-synucleinopathies -
Parkinson’s disease, dementia with Lewy bodies and pure autonomic failure - are characterized 
by neuronal α-synuclein aggregates, generally known as Lewy bodies [1, 10].
The unifying histopathological hallmark of MSA is the appearance of α-synuclein positive GCI 
in affected brain regions including striatonigral and/or olivopontocerebellar systems. Incidence 
of GCI is well correlated with disease severity and duration in the early stages of the disease [54, 
55].
The mechanisms underlying MSA still remain elusive. However, the evidence from preclinical 
models and postmortem studies suggests that it is a primary oligodendrogliopathy [56, 57]. Early 
myelin alterations in MSA brain have been demonstrated by the presence of altered myelin basic 
protein p25α, an important stabilizer of myelin integrity [57]. The p25α protein has been shown 
to colocalize with α-synuclein-positive CGI and to accumulate abnormally in MSA 
oligodendrocytes [58, 59, 60, 61]. Relocalization of p25α into the oligodendroglial soma appears 
to precede α-synuclein aggregation [62]. This is followed by oligodendrocyte swelling and 
abnormal uptake or overexpression of α-synuclein by oligodendroglia [63, 64]. The interaction 
between p25α and α-synuclein promotes phosphorylation and aggregation of α-synuclein into 
insoluble oligomers first and glial cytoplasmic inclusions later on. The formation of GCI 
interferes with neuronal support and has activation effect on quiescent microglial cells. Further 
on progressively dysfunctional oligodendrocytes release misfolded α-synuclein into the 
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extracellular space and this misfolded α-synuclein may be taken up by neighboring neurons to 
form neuronal cytoplasmic inclusions. The processes of neuroinflammation, loss of 
oligodendroglial neurotrophic support, and neuronal dysfunction due to α-synuclein inclusions 
together may synergistically promote neuronal death and subsequent reactive astrogliosis. Toxic 
α-synuclein species may spread in a prion-like fashion to other functionally connected brain 
areas, leading to the multisystemic neuronal impairment [65].
1.5. Diagnostic Considerations
The diagnosis of MSA is based largely on history and neurological examination. The consensus 
guidelines specify three degrees of certainty: definite, probable, and possible [1, 19]. Diagnosis 
of definite multiple-system atrophy requires neuropathological evidence of widespread α-
synuclein – positive GCI with presence of neuronal multisystem changes: striatonigral 
degeneration or olivopontocerebellar atrophy [1, 19]. 
Probable MSA is defined as sporadic, adult-onset and relatively rapidly progressive disorder 
having prominent autonomic dysfunction with combinations of parkinsonian features (MSA-P) 
or cerebellar ataxia (MSA-C). Autonomic dysfunction required for probable MSA must include 
urinary incontinence and/or severe OH, defined as a blood pressure decrease of 30 mmHg 
systolic or 15 mmHg diastolic within 3 minutes after active standing from the recumbent position 
(Table II).
A diagnosis of possible MSA requires the presence of a sporadic, progressive, adult-onset 
disorder with predominant parkinsonism or cerebellar ataxia, which has at least one feature 
suggestive of autonomic dysfunction and at least one of supportive features (warning signs) 
(Table II). 
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Table II. Diagnostic Approach to MSA. 
Definite MSA
Neuropathological findings during postmortem examination with the evidence of:
▪Widespread and abundant cerebral α-synuclein–positive GCI
▪Neuronal changes: striatonigral degeration or olivopontocerebellar atrophy
Probable MSA
Sporadic, progressive disease in adults (onset after 30 years of age) characterized by autonomic 
failure, including urinary incontinence (with erectile dysfunction in men), or an orthostatic 
decrease in blood pressure by at least 30 mmHg systolic or 15 mmHg diastolic within 3 min of 
standing, plus one of the following:
▪Slowness, rigidity, and postural instability with poor response to levodopa (MSA-P)
▪Gait ataxia, uncoordinated limb movements, action tremor, and nystagmus (MSA-C)
Possible MSA
A sporadic, progressive, adult-onset disease characterized by the following:
▪Parkinsonism (slowness of movements, rigidity, and tendency to fall) or a cerebellar syndrome 
(wide-based gait, uncoordinated limb movements, action tremor, and nystagmus)
▪At least one feature suggesting autonomic dysfunction (otherwise unexplained urinary urgency 
or frequency, incomplete bladder emptying, erectile dysfunction in men, or a substantial 
orthostatic blood pressure decline that does not meet the level required for probable MSA)
At least one of the following additional features:
▪Possible MSA-P or MSA-C: Babinski sign with hyperreflexia, stridor
▪Possible MSA-P: rapidly progressive parkinsonism; poor response to levodopa; recurrent falls 
within 3 years after the onset of motor symptoms; cerebellar features (wide-based gait; 
cerebellar dysarthria; uncoordinated limb movements; or spontaneous, gaze-evoked, or 
positional downbeat nystagmus); recurrent choking within 5 years after the onset of motor 
symptoms; atrophy on MRI of the putamen, middle cerebellar peduncle, pons, or cerebellum; 
hypometabolism on FDG-PET in the putamen, brain stem, or cerebellum
▪Possible MSA-C: parkinsonism; atrophy on MRI of the putamen, middle cerebellar peduncle, 
or pons; hypometabolism on FDG-PET in the putamen; presynaptic nigrostriatal dopaminergic 
denervation on PET
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Features supporting and not supporting the diagnosis of MSA
▪Supporting (warning signs): head–neck dystonia; disproportionate antecollis; bent spine 
(forward, lateral, or both); contractures of the hands or feet; inspiratory sighs; severe dysphonia; 
severe dysarthria; new or increased snoring; cold hands and feet; emotional incontinence 
(pathologic laughter or crying); jerky, irregular postural or action tremor
▪Not supporting: classic “pill-rolling” rest tremor, clinically significant neuropathy, 
hallucinations not induced by drugs, onset after 75 years of age, family history of ataxia or 
parkinsonism, dementia (in accordance with DSM-IV criteria), white-matter lesions suggesting 
multiple sclerosis
1.6. Prognosis
Patients with MSA have a poor prognosis. Patients develop the disease when being usually older 
than 40 years (average 52-55 years) and they experience fast progression. The disease progresses 
by worsening of motor and non-motor symptoms during an average period of 10 years, with 
more rapid progression at the onset [66]. Approximately 50% of patients require walking aids 
within 3 years after the onset of motor symptoms [2]. 60% require a wheelchair after 5 years
[67]. The median time before the patient is bedridden is 6 to 8 years [2]. Median survivals of 6.2-
9.5 years from the onset of first symptoms have been reported [26]. There are reports of both 
aggressive variants with disease duration of less than 3 years [26] and more benign cases with 
prolonged survival [68]. Older age at onset [2, 67] a parkinsonian phenotype [65] and early 
development of severe autonomic failure [2, 69, 70] are negative prognostic factors, whereas a 
cerebellar phenotype and later onset of autonomic failure [68] predict slower disease 
progression. The overall striatonigral cell loss is associated with the severity of the disease at the 
time of death. Bronchopneumonia (48%) and sudden death (21%) are common terminal 
conditions in MSA. Sudden death often occurs at night as a result of either acute bilateral vocal-
cord paralysis or acute disruption of the brain-stem cardiorespiratory drive. Urinary dysfunction 
in MSA often leads to lower urinary tract infections. More than 50% of patients with MSA suffer 




When diagnosing MSA, paraclinical tests are of great importance to reject possible alternative 
causes of a neurological disorder. Cranial computerized tomography (CT) is useful to rule out 
MSA-mimicking brain lesions. CT could be normal in MSA. In about half of the patients 
however there may be atrophy of the brainstem, cerebellum, and rarely cerebral cortex. In 
general, sensitivity and specificity of CT are fairly low. All patients with suspected MSA should 
be investigated by magnetic resonance imaging (MRI) of the strength ≥ 1.5 Tesla. In T2-
weighted sequences atrophy of putamen, middle cerebellar peduncle, pons, or cerebellum, a so-
called “rim sign” (hyperintense signal of the dorsolateral border of putamen) and putaminal 
hypointensity could be seen in MSA-P brain. In MSA-C atrophy of putamen, middle cerebellar
peduncle or pons and “hot-cross-bun sign” (cruciform hyperintensity in the pons) are possibly 
present. "Rim sign" and "hot-cross-bun sign" have high specificity but low sensitivity for the 
diagnosis of MSA [71].
Positron emission tomography (PET) with appropriate radiotracers is proved to be useful in the 
differentiation of the patients with MSA from PD and controls [72]. Fluorodeoxyglucose-PET 
(FDG-PET) has substantial specificity to differentiate patients with parkinsonism as PD, MSA, 
progressive supranuclear palsy (PSP) or corticobasal degeneration (CBD) [73].
Cardiac sympathetic innervation visualized using myocardial 123I-metaiodobenzylguanidine 
(MIBG) scintigraphy [74, 75, 76] or F-dopamine PET [77] may help differentiating MSA-P from 
PD [78]. Normal cardiac radiotracer uptake indicates the presence of spared cardiac 
postganglionic sympathetic fibers in MSA, while most PD patients – even those without 
symptomatic dysautonomia – show a reduced cardiac postganglionic sympathetic innervation. 
The tests have however suboptimal diagnostic accuracy. Some PD patients may show normal 
cardiac MIBG uptake [79] whereas sympathetic cardiac denervation can occur in MSA as well 
[80].
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Demonstration of severe autonomic failure in different domains of autonomic regulation 
supports a presumptive diagnosis of MSA. Investigation of bladder function is necessary in 
patients with suspected MSA [81]. Urodynamic examination may show vesical detrusor 
overactivity, absence of detrusor–sphincter coordination, bladder atony usual in MSA. 
Videourodynamics can provide additional anatomical information in particular cases. Post-void 
residual volume needs to be determined by ultrasound examination. This test is recommended for 
patients reporting voiding difficulties. Postvoiding residual urine volume >100 ml is an 
important urological symptom in MSA [81]. Beside severe OH in orthostatic testing, which is 
described in previous paragraph, nocturnal hypertension in 24-hours blood-pressure monitoring,
impaired cardiovascular autonomic reflexes in Valsalva maneuver and reduced heart rate 
variability are characteristic cardiovascular autonomic abnormalities for the patients with 
suspected MSA [1]. 
Rapid eye movement (REM) sleep behavior disorder during polysomnography is of prognostic 
value in case of early premotor MSA. This test however has no specificity differentiating MSA-P 
and PD [82].
Impaired stimulation of growth hormone by clonidine or arginine has been reported to 
differentiate both MSA-P from PD and possibly MSA-C from idiopathic, late-onset cerebellar 
ataxia [19]. However the tests have suboptimal diagnostic accuracy and to date the available 
diagnostic protocols have not entered routine clinical practice.
In autonomic domain of thermoregulation thermoregulatory sweat test may reveal rapidly 
progressive failure of whole-body sweating, thus potentially differentiating MSA-P and PD [13].
Normal findings in quantitative sudomotor axon reflex test indicate sparing of skin 
postganglionic sympathetic innervation in MSA and could differentiate MSA-P from PD [79].
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1.8. Neuropathophysiology of Dysautonomia in MSA
The neuropathology of autonomic dysfunction in MSA has received considerable attention. 
Neurodegenerative changes of the dorsal nucleus of the vagus nerve and nucleus ambiguus have 
been determined [83]. Furthermore, some selected brainstem nuclei appear to be affected as well 
[84, 85, 86, 87]. Cholinergic cell loss at the mesopontine level (pedunculopontine tegmental 
nuclei/laterodorsal tegmental nuclei involved in the sleep control) has also been reported in MSA 
[87]. The hypothalamus is affected [88]. Few studies demonstrated a loss of arginine-vasopressin 
neurons in the posterior portion of the paraventricular nucleus and in the suprachiasmatic nucleus 
[84], and a loss of hypocretin/orexin neurons of the posterolateral hypothalamus [89]. All these 
cell populations are involved in circadian regulation of endocrine and autonomic functions. At 
lower levels of the autonomic nervous system, lesions are observed typically in sympathetic 
preganglionic neurons in the intermediolateral column of the thoracolumbar spinal cord that have 
been linked to OH [90]. Alpha-synuclein aggregates have been also reported in sympathetic 
ganglia of MSA brains [90, 91, 92]. Urogenital and sexual disorders have been related to 
neuropathological changes in parasympathetic preganglionic neurons of the spinal cord including 
Onuf’s nucleus [93, 94, 95].
1.9. Neuroanatomical Basics of Human Thermoregulation
Hypothalamus plays a central role for thermoregulatory responses in human body. The anterior 
hypothalamus contains both warm- and cold-sensitive neurons. Warm-sensitive neurons 
outnumber cold-sensitive neurons by a 3:1 ratio. Increased core temperatures are associated with 
increased firing rates of warm-sensitive neurons; cold-sensitive neurons increase their firing rates 
when core temperatures fall [96]. Afferent pathways for thermal receptors in the skin begin in the 
dorsal roots and ascend predominantly in the spinothalamic tracts. Thermal receptors in deep 
tissues such as the abdominal viscera may course through the vagus and splanchnic nerves before 
entering the central nervous system. Both skin and deep thermal receptor pathways terminate in 
the anterior and posterior hypothalamic areas. The posterior hypothalamus integrates signals 
from the skin, deep tissues and anterior hypothalamus, further the posterior hypothalamus 
triggers autonomic responses appropriate for temperature correction [97].
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The intermediolateral and intermediomedial cell columns of spinal segments T1 to L3 of the 
spinal cord are the origin of preganglionic sympathetic outflow involved in autonomic 
temperature regulation. These preganglionic neurons receive input from cell groups in the 
hypothalamus and brainstem, including the rostral ventrolateral medulla, rostral ventromedial 
medulla, caudal raphe nuclei, lateral and posterior hypothalamus, periaqueductal gray and 
preoptic area [98]. The axons of preganglionic neurons form the white rami communicantes that 
pass to the sympathetic trunk. Preganglionic axons may synapse with postganglionic neurons in 
the sympathetic ganglia and rejoin the spinal nerves as gray rami communicantes. Preganglionic 
axons may also ascend or descend the sympathetic trunk before making synapses on 
postganglionic neurons. Other preganglionic fibers course through the sympathetic ganglia and 
form the splanchnic nerves that synapse in the prevertebral ganglia [97]. 
Acetylcholine is the neurotransmitter released at preganglionic synapses on postganglionic 
neurons. Acetylcholine is also released by the postganglionic sympathetic innervation of sweat 
glands; norepinephrine is released by the vast majority of postganglionic nerves that innervate 
blood vessels. Other neurotransmitters, particularly peptides, may be released in combination 
with either acetylcholine or norepinephrine [97].
2. Differential Diagnostics of MSA-P and PD
Due to overlapping motor presentations it can be very challenging to distinguish MSA-P from 
PD. The cardinal MSA autonomic symptoms - OH and urinary incontinence - are of limited 
assistance while these symptoms are common among the PD patients as well [99]. Neuroimaging 
modalities, like MIBG scintigraphy, do not always provide a certain differentiation between 
these two diseases as well [100, 101, 102].
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In PD, alike MSA, there can be failure or dysregulation in some different autonomic domains. 
Autonomic abnormalities for PD patients may also include constipation, heat or cold intolerance, 
postprandial hypotension and relative nocturnal hypertension [103, 104]. Pathophysiologically 
PD involves a peripheral catecholaminergic lesion with the loss of postganglionic sympathetic 
noradrenergic neurons and parasympathetic cholinergic denervation [105, 106].
Contemporary studies agree that ordinary autonomic testing can hardly help differentiating 
MSA-P and PD with autonomic failure [106]. The role of specific and sophisticated evaluation 
of different autonomic domains remains rather controversial [13, 102]. 
As reported in previous publications, disturbed neurovascular thermoregulation of distal 
extremities belongs to MSA autonomic features [14, 15]. Hand skin temperature and its response 
to cooling in subjects with probable MSA-P and PD were compared determining significant 
differences regarding hand temperature before and after cooling, as well as kinetics of natural 
rewarming [14, 15]. To date only a minor study sample has been reported. The prevalence of 
disturbed neurovascular thermoregulation in sizeable patient cohorts remained obscure. 
The methodology for testing hand skin temperature and its response to cooling has been 
established in some specialized medical centers and routinely used examining patients with 
parkinsonian syndromes. This is a retrospective study, which was conducted on the patients from 
a specialized neurological acute care hospital, recruited from August, 1997 until July, 2015.
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II. PATIENTS AND METHODS
1. Objectives 
To improve our knowledge about impaired thermoregulation of distal extremities in MSA-P and 
PD.
To assess the coexistence and possible interrelations for the different subtypes of autonomic 
dysfunction in a large cohort of MSA-P, PD and control patients.
2. Patients 
Study cohort comprises 577 patients diagnosed with PD according to the UK PD Society Brain 
Bank diagnostic criteria (PD group) [107], 130 probable MSA-P patients (MSA-P group) [19]
and 150 patients having insufficient clinical evidence of a possible α-synucleinopathy or other 
neurodegenerative disease (control group). The complaints of the control patients after a 
thorough clinical assessment were addressed to a cerebrovascular disease, neurological 
complications of diabetes or functional disorders. In the follow-up the controls developed no 
signs of a neurodegenerative disease. Demographical and anamnestic data of the patients are 
presented in Table 1. Over the course of the follow-up in the study groups the overlapping of 
parkinsonian syndromes could be largely excluded. 
All the patients were recruited in the Parkinson’s Disease Clinic Ortenau, Germany. The 
retrospective recruitment extended from August, 1997 until July, 2015. This study was carried 
out in accordance with the approved guidelines of the university research ethics committee.
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MSA group PD group Control group p-value
Age, Years












































Table 1. Demographical data and clinical findings. Data represented as Mean ± Standard 
Deviation. Unequal subscript letters indicate significant differences between groups.
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3. Methods
At the beginning of the retrospective recruitment there was no specific disability rating scale for 
the MSA patients available. Instead we have used Unified Parkinson’s Disease Rating Scale 
(UPDRS) for the MSA and the PD study groups.
All patients underwent a standard cooling - rewarming procedure, termed ice test (IT). Hand skin 
temperature was initially measured at rest with a digital thermometer (Quigg TS 402) adhered to 
the palmar surface of the third finger in patient's left hand. Then the hand was cooled between 
two standardly prepared ice packs for 5 minutes (Picture 1). 
Picture 1. Performing the IT.
Directly after removal from the ice packs, hand temperature was measured again and the hand 
was left over to rewarm naturally. The measurements were repeated consequently on the 7th, 9th, 
11th, 13th and 15th minute of the IT. Some percentage of the patients did not tolerate IT because 
of painful, unpleasant sensations related to cooling. In such a case the IT was discontinued 
annotating initial hand temperature (Table 2). All the measurements were performed in a 
specialized room with controlled temperature (20°C) and neutral humidity. Patients were tested 
in the morning while they were fasting and had not taken their morning medications.
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MSA group PD group Control group p-value
Ice test completed
Ice test discontinued














Temperature decrement in 
pathological IT, ºC
Time to full rewarming, min






































































Table 2. The prevalence of pathological IT, the frequencies of gradually increasing temperature 
decrement and evaluation parameters of natural rewarming in the three study groups. Data 
represented as Mean ± Standard Deviation.
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Once the hand temperature at the end of 15-minute IT was lower than the initial temperature at 
rest, IT was stated to be pathological in terms of defective neurovascular regulation. As a result 
temperature decrement (initial minus endpoint temperature) was noted. Time to complete 
rewarming was noted for the patients who after the cooling recovered back to the initial hand 
temperature earlier than the end of the IT. Considering kinetics of natural rewarming temperature 
increment rate (endpoint temperature minus temperature directly after the cooling per time to 
complete rewarming) was calculated (Table 2).
Furthermore, the subdivision of the patients received peripheral and autonomic nervous systems 
evaluated (Table 3). 
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MSA group PD group Control group p-value
Orthostatic hypotension
Suppressed SSR
Reduced heart rate 
variability
Peripheral neuropathy
12 out of 18
(66.67%a)
64 out of 80
(80.00%a)
67 out of 74
(90.54%)
33 out of 76
(43.42%)
38 out of 116
(32.76%b)
144 out of 219 
(65.75%b) 
106 out of 124
(85.48%)
146 out of 344
(42.44%) 
4 out of 15
(26.67%b)
34 out of 54
(62.96%b)
23 out of 30
(76.67%)






Table 3. Autonomic disturbances and peripheral neuropathy in the three study groups. Unequal 
subscript letters indicate significant differences between groups.
The evaluation included autonomic function test of heart rate variability, based on time-domain 
analysis of directly measured heart periods [108, 109], which are considered as measurements 
predominantly reflecting parasympathetic modulation of the heart [108].
Electrophysiologic sympathetic skin response (SSR) test was deployed to assess the reflex 
activity of sympathetic sudomotor pathways [110, 111, 112, 113, 114]. This test has been used in 
various peripheral and central neurologic disorders [115, 116, 117, 118, 119, 120]. Studies have 
been performed on PD and MSA patients [121], showing marked qualitative and quantitative 
SSR abnormalities, including suppression of SSR amplitudes (suppressed SSR) or even loss of 
response in these diseases [122]. SSR is a multisynaptic reflex that assesses the function of the 
sympathetic sudomotor pathways [110, 111, 112, 113]. The SSR afferent component depends on 
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the type of stimulus. At a central level, different structures, such as the reticular formation, 
limbic cortex, and posterior hypothalamus, seem to be involved. The efferent pathway consists of 
preganglionic and postganglionic sympathetic neurons and peripheral C fibers, innervating the 
sweat glands and acting as terminal efferents of the reflex [122, 123, 124]. In this study SSR was 
elicited by electrical stimulation of the median nerve and simultaneously recorded on the palm, 
corresponding to the previously described methodology [121].
To evaluate orthostasis, lying-to-standing orthostatic test was performed according to the 
international consensus on the definition and diagnosis of OH [125]. Patients laid down 10 min 
and systolic blood pressures (SBP) were measured three times within. After active standing SBP 
was measured immediately and consequently at each minute while patients stand motionless for 
10 min. The severity of OH was expressed in the maximal drop of SBP after standing up from 
the supine position as the mean of the three measurements.
Electroneurography was deployed in detection of axonal peripheral neuropathy [126]. 
4. Statistical Analysis
Statistical analyses were performed using the statistical software IBM SPSS Statistics 23 
(Armonk, NY: IBM Corp. Software). Data are presented as Mean (M) ± Standard Deviation 
(SD).
After testing for normality continuous variables were compared with the Student’s t-test and 
ANOVA for independent or related groups. For the skewed data nonparametric criteria including 
Mann-Whitney U-test, Kruskal-Wallis 1-way ANOVA or Friedman's test were used when 
appropriate to compare quantitative samples.
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The correlations or associations among the investigated parameters were evaluated by using 
Pearson's correlation coefficient (r) or Contingency coefficient. To test hypotheses about 
independence the chi-square testing was applied. For pairwise comparison of proportions z-test 
was used. The level of statistical significance was set to 0.05.
III. RESULTS
The mean age of the MSA patients was 67.07±7.78 years (Mean ± Standard Deviation). The 
patients in the MSA study group were significantly younger (p = 0.001) than the PD and the 
control group patients (70.37±8.97 and 74.84±6.92 years, respectively). 
The medical history of arterial hypertension, diabetes and medicated hypothyroidism were 
similarly common in the MSA and the PD study groups (Table 1).
PD patients had median Hoehn and Yahr stage 3; staging histogram for the PD patients is 
presented in Figure 1. Likewise, Hoehn and Yahr staging was applied for 41 patients in the MSA 
study group (Figure 2). 
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Figure 1. Hoehn and Yahr staging histogram for the PD study group.
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Figure 2. Hoehn and Yahr staging histogram for the MSA study group.
The MSA patients had higher UPDRS motor and total scores than the PD patients (p < 0.001). 
In the PD group the history of L-dopa medication was available for 275 patients. 28 out of 275 
patients did not receive L-dopa, for the rest the mean L-dopa daily dose was 463.25±184.20 mg. 
Similarly, the history of L-dopa medication was available for 88 MSA patients. 9 patients 
received no L-dopa, for the rest 79 patients the mean L-dopa daily dose was 651.66± 293.61 mg 
(p < 0.001, Figure 3). For PD and MSA study groups L-dopa consumption histograms are shown 
in Figures 4 and 5.
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Figure 3. Mean L-dopa daily dose in the PD and the MSA study groups, p < 0.001.
Figure 4. L-dopa consumption histogram for the PD study group.
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Figure 5. L-dopa consumption histogram for the MSA study group.
Principally used dopamine agonists in the MSA and the PD study groups are presented in Table 
4.

























Table 4. Dopamine agonists used in the MSA and the PD study groups.
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Initial hand skin temperature histograms for the three study groups are shown in Figure 6 A, B 
and C. The probability distributions of initial hand skin temperature in MSA, PD and control 
study groups are presented in the Appendix.
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Figure 6 A, B and C. Initial hand skin temperature histograms in MSA, PD and control study 
groups respectively. 
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In MSA, PD and control study groups the hand skin temperatures measured at rest (30.75±3.35; 
30.11±3.09 and 30.59±3.13°C, respectively, p = 0.072, Figure 7), immediately after the cooling 
(13.87±7.64; 13.86±6.66 and 13.96±7.18°C, respectively, p = 0.99) and subsequently at each 
measurement during natural rewarming did not differ significantly (Table 5, Figure 8). 
Figure 7. Initial hand skin temperature means for the three study groups, p = 0.072.
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MSA group PD group Control group
Mean, °C Std. Dev., °C Mean, °C Std. Dev., °C Mean, °C Std. Dev., °C
Initially 30.75 3.35 30.11 3.09 30.59 3.13 *
5 min. 13.86 7.64 13.86 6.66 13.96 7.18 *
7 min. 19.78 8.10 19.91 7.36 20.40 7.91 *
9 min. 23.83 7.13 23.87 6.69 24.43 7.11 *
11 min. 26.22 6.33 26.14 5.99 26.69 6.25 *
13 min. 27.80 5.83 27.66 5.37 28.06 5.46 *
15 min. 28.71 5.22 28.62 4.98 28.82 5.05 *
5 min., % 44.80 23.57 45.52 19.94 44.81 20.86 *
7 min., % 63.78 24.10 65.48 21.31 65.60 22.11 *
9 min., % 77.02 20.45 78.71 18.77 79.14 19.38 *
11 min., % 85.03 17.86 86.43 16.35 86.74 16.35 *
13 min., % 90.31 16.31 91.61 14.16 91.43 13.73 *
15 min., % 93.33 14.11 94.93 12.93 94.03 12.51 *
Table 5. Hand skin temperatures initially at rest and at each measurement of the IT. The 
percentage temperature values at each point after the cooling. Std. Dev. Standard Deviation. 
* denotes p > 0.05.
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Figure 8. Hand temperature means in the course of IT.
Despite the absence of consistent group difference, to evaluate the kinetics of cooling and 
rewarming accurately, hand temperature at each measurement of the IT was expressed as the 
percentage of initial resting hand temperature. The percentage values at each point after the 
cooling were consistently, but not significantly lower in the MSA group (Table 5, Figure 9). 
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Figure 9. Hand temperature means expressed as the percentage of initial resting hand 
temperature.
The prevalence of pathological IT was higher in the MSA than in the PD and the control groups, 
the difference, however, was not statistically significant (58.93%; 52.0% and 56.59%, 
respectively, p = 0.33). 
Patients in the MSA study group were significantly younger than the PD patients and the 
controls. To alleviate the possible influence of age, we have arranged all the study patients into 
three preset age-layers of younger than 65; 65 - 75; and older than 75 years of age. Further, we 
have compared the prevalence of pathological IT between the three study groups in the each age-
layer separately and found no significant relation for the study group and the IT result (p = 0.21; 
0.14 and 0.32, respectively).
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In the study cohort the patients having a pathological IT had a significantly lower hand 
temperature already before the cooling compared to the patients with a non-pathological IT 
(29.92±3.26 and 30.73±2.90°C, respectively, p < 0.001). IT for the patients whose initial hand 
temperature was abnormally low (≤  29.92°C) and who afterwards did not tolerate the cooling 
were consequently assumed to be pathologic. In such a manner the prevalence of pathologic IT 
in the three study groups was re-evaluated remaining not significantly higher in the MSA group 
(60.0%; 54.0% and 58.59%, respectively, p = 0.24).
Hypothesizing that potentially the pathological IT gains more specificity in the differentiation of 
MSA versus PD along with the gradually increasing temperature decrement, the frequencies of 
temperature decrement ≥ 1, 2, ..., 11°C in the three study groups were estimated. The frequencies 
of gradually increasing temperature decrement were consistently higher in the MSA group, the 
differences remained not sufficient for a statistical significance (Table 2). The greatest 
temperature decrement observed in the study cohort was 17.4°C (the PD group).
Defective thermal regulation of distal extremities could possibly occur due to conditions such as 
hypothyroidism, known peripheral neuropathy, diabetes and possible diabetic cutaneous 
microangiopathy, which are merely associated with autonomic dysfunction [14, 15, 127]. To 
avoid this potential confusion we have re-evaluated the prevalence of pathological IT excluding 
the patients with treatment for hypothyroidism and diabetes in their medical history or with 
detected peripheral neuropathy. Still, the results remained similar, there was no statistically 
significant difference for the prevalence of pathological IT in the three study groups observed 
(62.50%; 56.20% and 48.48%, respectively, p=0.52).
Neither the presence of pathological IT, nor the temperature decrement in case of pathological IT 
were associated with the L-dopa daily dose or the principally used dopamine agonist in the MSA 
and the PD study groups.
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In the PD group the presence of pathological IT was related with older patient's age (p < 0.001), 
older age at onset of disease (p < 0.001), higher UPDRS motor (p = 0.007) and total scores (p = 
0.002). Interestingly, there was no such relation in the MSA group observed. In the control group 
the presence of pathological IT was related to patient's age in a statistically significant manner (p 
= 0.034). 
A significant association for the presence of pathologic IT and suppressed SSR in the study 
cohort was determined (p = 0.003). The rate of suppressed SSR itself was significantly higher in 
the MSA group compared to the PD and the control groups (80.00%; 65.75% and 62.96%, 
respectively, p = 0.04) (Table 3).
There was no statistically significant relation between the pathological IT and the history of 
arterial hypertension, diabetes, medicated hypothyroidism or detected peripheral neuropathy 
neither in the three study groups separately, nor in the study cohort observed. An association for 
the pathological IT and patient's gender could not be determined.
In the study cohort we observed a significant association between the presences of pathological 
IT and the symptom of orthostatic hypotension (p < 0.001). The association remained 
statistically significant in the PD study group (p < 0.01). To evaluate the influence of possible 
confounders (patient's age, age at onset of disease, disease duration, UPDRS motor and total 
scores, history of arterial hypertension, hypothyroidism, diabetes and detected peripheral 
neuropathy) we performed multivariate logistic regression analysis. These confounders were 
determined having no significant influence (p > 0.05).
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In case of pathologic IT and a drop of systolic blood pressure after active standing in orthostatic 
test there was no statistically significant correlation for the temperature decrement and the 
maximal drop of systolic blood pressure determined (p = 0.27). 
The symptom of OH was significantly more prevalent in the MSA than in the PD and the control 
groups (66.67%, 32.76% and 26.68%, respectively, p = 0.015). Male patients suffered from OH 
more often than female patients (p = 0.001). The symptom of OH was not related with the 
history of arterial hypertension, diabetes, hypothyroidism as well as with the detected peripheral 
neuropathy, reduced heart rate variability and suppressed SSR in a statistically significant 
manner. Neither the OH itself, nor the maximal drop of systolic blood pressure after active 
standing were associated with the L-dopa daily dose nor with the principally used dopamine 
agonist in the MSA and the PD study groups. 
In the MSA group the severity of OH expressed in the maximal drop of systolic blood pressure 
after active standing tended to correlate with older patient's age (p = 0.051, r = 0.48) and 
correlated with older age at onset of disease significantly (p = 0.029, r = 0.53). For the PD 
patients suffering from OH the significant correlation regarding the severity of OH and patient's 
age, age at onset of disease or disease duration could not be determined.
In the MSA and the PD groups the presence of suppressed SSR was associated with the detected 
peripheral axonal neuropathy significantly (p = 0.044 and 0.018, respectively). Such a correlation 
however was absent in the control study group. 
Presence of peripheral axonal neuropathy was not associated with the L-dopa daily dose in the 
MSA (p = 0.18) and the PD (p = 0.92) study groups significantly (Figures 10 and 11).
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Figure 10. Mean L-dopa daily dose for the MSA patients without and with the detected 
peripheral axonal neuropathy, p = 0.18.
Figure 11. Mean L-dopa daily dose for the PD patients without and with the detected peripheral 
axonal neuropathy, p = 0.92.
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The prevalence of reduced heart rate variability was higher in the MSA than in the PD and the 
control groups, but did not differ significantly (90.54%; 85.48% and 76.67%, respectively, p > 
0.05) (Table 3).
IV. DISCUSSION
MSA together with PD, Lewy body dementia and pure autonomic failure form a group of 
neurodegenerative disorders - the α-synucleinopathies, characterized by the abnormal 
accumulation of misfolded α-synuclein. A definitive diagnosis of MSA requires the 
neuropathological findings of widespread α-synuclein positive glial cytoplasmic inclusions 
associated with neurodegenerative changes in striatonigral or olivopontocerebellar structures 
[128]. Furthermore, neurodegenerative changes affect the central autonomic nervous system, 
including the hypothalamus, brain-stem nuclei, dorsal nucleus of the vagus nerve, nucleus 
ambiguus, Onuf’s nucleus and sympathetic preganglionic neurons in the intermediolateral 
column of thoracolumbar spinal cord [1, 129, 130]. Autonomic dysfunction in PD though seems 
to be caused mainly by the postganglionic lesion [13, 131].
Due to overlapping motor presentations it can be very challenging to distinguish MSA from PD. 
The cardinal MSA autonomic symptoms - OH and urinary incontinence - are of limited 
assistance while these symptoms are common among the PD patients as well [99]. Neuroimaging 
modalities, like MIBG scintigraphy, do not always provide a certain differentiation between 
these two diseases [100, 101, 102].
The results reveal the disturbed neurovascular thermoregulation of distal extremities as shown by 
the pathological IT to be highly prevalent for the MSA and the PD patients. The prevalence of 
pathological IT was slightly increased in the MSA group compared with the PD and the control 
groups. The frequencies of gradually increasing temperature decrement were consistently higher 
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in the MSA group. The mean temperature decrement in pathological IT was also higher for the 
MSA patients, although there were no statistically significant differences observed. This study 
shows that despite the substantial overlap the autonomic feature of defective thermoregulation is 
more severe in the MSA patients. The underlying pathophysiology remains rather incompletely 
understood. 
The results of this work however disagree with the previously published study [14], which 
observed significantly lower initial hand skin temperature, greater reduction of hand temperature 
after cooling and significantly prolonged rewarming for the MSA patients compared with the PD 
patients and the controls. The previous study reported only a minor study sample though. 
Having in mind the observed pattern of natural rewarming (Figures 8 and 9), which was quite 
similar in the three study groups during 10 minutes after the cooling, extending temperature 
observation should be considered to increase the specificity of pathological IT. To unify the 
conditions in the three study groups, the IT was performed on the left hand for all the patients. In 
patients with motor asymmetry the association between the presence of pathological IT and more 
affected side seems to be probable and should be further investigated to get more insight into the 
pathology causing impaired thermoregulation. Furthermore, a considerable percentage of the 
patients did not tolerate IT because of painful, unpleasant sensations related to cooling. It could 
be beneficial to quantify the patients' painful sensations experienced in the course of the IT 
using, for example, the Numeric Pain Rating Scale [132].
At the beginning of the retrospective recruitment for this study there was no specific disability 
rating scale to rate the MSA patients available. Instead we have used UPDRS for the MSA and 
the PD study groups. The major disadvantage of UPDRS is that this scale imperfectly reflects the 
complex motor impairment of MSA. On the other hand, thereby we have achieved the uniform 
comparison between the MSA and the PD patients.
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The presence of pathological IT was significantly associated with older patient's age in the PD 
and the control study groups. This was not the case for the MSA patients, who themselves were 
significantly younger than the patients of the PD and the control groups. Defective 
thermoregulation appears to be an intrinsic factor to MSA. Furthermore it should be considered 
in aging patients with PD and in aging population comprehensively.
Patients in the MSA study group were significantly younger than the PD patients and the 
controls. We have tried to alleviate the possible influence of age to the comparison of the study 
groups by analyzing the prevalence of pathological IT in the preset age-layers. However, 
younger age and more rapid deterioration constitute some particular feature for the MSA.
In the study cohort pathologic IT was significantly associated with the suppressed SSR. It is 
reported that SSR to electric stimulation are mediated through the efferent pathway consisting of 
preganglionic and postganglionic sympathetic neurons. The amplitudes of responses are 
suppressed or responses could be even absent when disturbance in efferent pathway occurs [122, 
123]. Based on the results we can hypothesize that preganglionic sympathetic neurons might be 
involved in the pathological mechanisms responsible for impaired response to cooling in MSA. 
This is the first study to determine a significant association between the presence of pathological 
IT and the symptom of OH. The results suggest a pathophysiological affinity between these two 
types of autonomic dysfunction, which again could be a defective sympathetic neurovascular 
regulation. We did not find any other numeric values of temperature decrement in pathological 
IT and maximal drop of systolic blood pressure after active standing from supine position, 
therewith these two pathophysiologically related symptoms could correlate each other stronger 
than with the contemporary consensus values of temperature decrement ≥ 0 °C and drop of 
systolic blood pressure ≥ 20 mmHg.
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The severity of OH expressed in maximal drop of systolic blood pressure tended to correlate 
with older patient's age and correlated with older age at onset of disease significantly in the MSA 
group. In compliance with the recent publications for the PD patients suffering from OH no
significant correlation between the severity of OH and patient's age, age at onset of disease or 
disease duration has been determined [10, 133]. In the PD group the severity of OH seems to 
show no significant advance with the disease duration.
OH and suppressed SSR were significantly more prevalent in the MSA group. Abnormalities in 
different domains of autonomic regulation, like pathologic IT and reduced heart rate variability, 
were more common among the MSA patients than in the PD and the control study groups, thus 
adding more evidence on the multisystemic nature of underlying neuropathology.
To sum up, the abnormal IT provides supplementary information on the extent of autonomic 
failure. Widespread and well documented dysautonomia should increase specificity in the 
distinction of MSA-P and PD. Accurate antemortem diagnosis of MSA remains of great 
importance defining patient's prognosis or enrolling in particular clinical trials.
The considerable strengths of this study are that the data from sizeable cohort of MSA-P, PD and 
control patients were available for analysis and the study patients all were recruited in the 
neurological department, specialized for the management of parkinsonian syndromes.
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Conclusions
Due to overlapping motor presentations it can be very challenging to distinguish MSA-P from 
PD, especially when PD also involves the autonomic nervous system.
Defective thermoregulation of distal extremities seems to be more severe in the MSA patients. 
So-called ice test however does not differentiate MSA-P and PD reliably.
Preganglionic sympathetic neurons might be involved in the pathological mechanisms 
responsible for impaired response to cooling in MSA.
The results suggest pathophysiological affinity of impaired sympathetic neurovascular regulation 
between pathological IT and OH.




Figure 1a. Probability plot of initial hand skin temperature in MSA study group
Figure 2a. Probability plot of initial hand skin temperature in PD study group.
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Figure 3a. Probability plot of initial hand skin temperature in control study group.
Figure 4a. Detrended probability plot of initial hand skin temperature in MSA study group
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Figure 5a. Detrended probability plot of initial hand skin temperature in PD study group




Analysis of variance (ANOVA)
Computerized tomography (CT)
Corticobasal degeneration (CBD)
Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV)
Fluorodeoxyglucose (FDG)
Glial cytoplasmic inclusions (GCI)
Ice test (IT)
Magnetic resonance imaging (MRI)
Mean (M) 
Multiple system atrophy (MSA)
Multiple system atrophy with cerebellar features (MSA-C)




Positron emission tomography (PET)
Progressive supranuclear palsy (PSP) 
Rapid eye movement (REM) 
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Shy-Drager syndrome (SDS)
Sympathetic skin response (SSR) 
Systolic blood pressure (SBP)
Standard Deviation (SD)
Striatonigral degeneration (SND)
Unified MSA Rating Scale (UMSARS)
Unified PD Rating Scale (UPDRS)
51
VII. REFERENCES
1. Fanciulli A, Wenning GK. Multiple-system atrophy. N Engl J Med 2015;372(14):1375-6.
2. Watanabe H, Saito Y, Terao S, et al. Progression and prognosis in multiple system atrophy: an 
analysis of 230 Japanese patients. Brain 2002;125:1070–83.
3. Tsuji S, Onodera O, Goto J, et al. Sporadic ataxias in Japan – a population-based 
epidemiological study. Cerebellum 2008;7(2):189–97.
4. Köllensperger M, Geser F, Ndayisaba JP, et al. Presentation, diagnosis, and management of 
multiple system atrophy in Europe: final analysis of the European multiple system atrophy 
registry. Mov Disord 2010;25:2604-12.
5. Wenning GK, Tison F, Ben Shlomo Y, Daniel SE, Quinn NP. Multiple system atrophy: a 
review of 203 pathologically proven cases. Mov Disord 1997;12:133-47.
6. Boesch SM, Wenning GK, Ransmayr G, Poewe W. Dystonia in multiple system atrophy. J 
Neurol Neurosurg Psychiatry 2002;72:300-3.
7. Köllensperger M, Geser F, Seppi K, et al. Red flags for multiple system atrophy. Mov Disord 
2008;23:1093-9.
8. Sakakibara R, Hattori T, Uchiyama T, et al. Urinary dysfunction and orthostatic hypotension 
in multiple system atrophy: which is the more common and earlier manifestation? J Neurol 
Neurosurg Psychiatry 2000;68 (1):5-9.
9. Freeman R. Clinical practice. Neurogenic orthostatic hypotension. N Engl J Med 
2008;358:615-24.
10. Jost WH, Augustis S. Severity of orthostatic hypotension in the course of Parkinson's 
disease: no correlation with the duration of the disease. Parkinsonism Relat Disord 
2015;21(3):314-6.
11. Goldstein DS, Pechnik S, Holmes C, Eldadah B, Sharabi Y. Association between supine 
hypertension and orthostatic hypotension in autonomic failure. Hypertension 2003;42:136-42.
52
12. Sakakibara R, Odaka T, Uchiyama T, et al. Colonic transit time, sphincter EMG, and 
rectoanal videomanometry in multiple system atrophy. Mov Disord 2004;19:924-9.
13. Lipp A, Sandroni P, Ahlskog JE, et al. Prospective differentiation of multiple system atrophy 
from Parkinson disease, with and without autonomic failure. Arch Neurol 2009;66:742-50.
14. Klein C, Brown R, Wenning G, Quinn N. The “cold hands sign” in multiple system atrophy. 
Mov Disord 1997; 12:514-8.
15. Pietzarka K, Reimann M, Schmidt C, et al. The cold hand sign in multiple system atrophy: 
skin perfusion revisited. J Neural Transm (Vienna) 2010;117(4):475-9.
16. Graham JG, Oppenheimer DR. Orthostatic hypotension and nicotine sensitivity in a case of 
multiple system atrophy. J Neurol Neurosurg Psychiatry 1969;32(1):28–34.
17. Papp MI, Kahn JE, Lantos PL. Glial cytoplasmic inclusions in the CNS of patients with 
multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-
Drager syndrome). J Neurol Sci 1989;94(1–3):79–100.
18. Gilman S, Low P, Quinn N, et al. Consensus statement on the diagnosis of multiple system 
atrophy. Clin Auton Res 1998;8:359–62.
19. Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of 
multiple system atrophy. Neurology 2008;71(9):670–6.
20. Wenning GK, Tison F, Seppi K, et al. Development and validation of the Unified Multiple 
System Atrophy Rating Scale (UMSARS). Mov Disord 2004;19(12):1391-402.
21. Stefanova N, Tison F, Reindl M, et al. Animal models of multiple system atrophy. Trends 
Neurosci 2005;28(9):501–6.
22. Dodel R, Spottke A, Gerhard A, et al. Minocycline 1 Year Therapy in Multiple- System-
Atrophy: Effect on Clinical Symptoms and [11C] (R)-PK11195 PET (MEMSA-Trial). Mov 
Disord 2010;25(1):97–107.
23. Bensimon G, Ludolph A, Agid Y, et al. Riluzole treatment, survival and diagnostic criteria in 
Parkinson plus disorders: the NNIPPS study. Brain 2009;132(1):156–71.
53
24. Gilman S, May SJ, Shults CW, et al. The North American Multiple System Atrophy Study 
Group. J Neural Transm 2005;112:1687–94.
25. Scholz SW, Houlden H, Schulte C, et al. SNCA variants are associated with increased risk 
for multiple system atrophy. Ann Neurol 2009;65(5):610–14.
26. Wenning GK, Ben Shlomo Y, Magalhaes M, et al. Clinical features and natural history of 
multiple system atrophy. An analysis of 100 cases. Brain 1994;117(4):835–45.
27. Bower JH, Maraganore DM, McDonnell SK, et al. Incidence of progressive supranuclear 
palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology 
1997;49(5):1284–8.
28. Schrag A, Ben-Shlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and 
multiple system atrophy: a crosssectional study. Lancet 1999;354:1771–5.
29. Brown RC, Lockwood AH, Sonawane BR. Neurodegenerative diseases: an overview of 
environmental risk factors. Environ Health Perspect 2005;113:1250–6.
30. Hanna PA, Jankovic J, Kirkpatrick JB. Multiple system atrophy: the putative causative role 
of environmental toxins. Arch Neurol 1999;56:90–4.
31. Nee LE, Gomez MR, Dambrosia J, et al. Environmental-occupational risk factors and 
familial associations in multiple system atrophy: a preliminary investigation. Clin Auton Res 
1991;1:9–13.
32. Vanacore N. Epidemiological evidence on multiple system atrophy . J Neural Transm 
2005;112:1605–12.
33. Chrysostome V, Tison F, Yekhlef F, et al. Epidemiology of multiple system atrophy: a 
prevalence and pilot risk factor study in Aquitaine, France. Neuroepidemiology 2004;23:201–8.
34. Vidal JS, Vidailhet M, Elbaz A, et al. Risk factors of multiple system atrophy: a case-control 
study in French patients. Mov Disord 2008;23:797–803.
35. Wenning GK, Wagner S, Daniel S, et al. Multiple system atrophy: sporadic or familial? 
Lancet 1993;342:681.
54
36. Gilman S, Sima AA, Junck L, et al. Spinocerebellar ataxia type 1 with multiple system 
degeneration and glial cytoplasmic inclusions. Ann Neurol 1996;39:241–55.
37. Itoh K, Kasai T, Tsuji Y, et al. Definite familial multiple system atrophy with unknown 
genetics. Neuropathology 2014;34:309-13.
38. Stemberger S, Scholz SW, Singleton AB, Wenning GK. Genetic players in multiple system 
atrophy: unfolding the nature of the beast. Neurobiol Aging 2011;32(10):1924-1926.
39. Kamm C, Healy DG, Quinn NP, et al. The fragile X tremor ataxia syndrome in the 
differential diagnosis of multiple system atrophy: data from the EMSA Study Group. Brain 
2005;128:1855–60.
40. Khan NL, Giunti P, Sweeney MG, et al. Parkinsonism and nigrostriatal dysfunction are 
associated with spinocerebellar ataxia type 6 (SCA6). Mov Disord 2005;20:1115–19.
41. Lee WY, Jin DK, Oh MR, et al. Frequency analysis and clinical characterization of 
spinocerebellar ataxia types 1, 2, 3, 6, and 7 in Korean patients. Arch Neurol 2003;60:858–63.
42. Nirenberg MJ, Libien J, Vonsattel JP, et al. Multiple system atrophy in a patient with the 
spinocerebellar ataxia 3 gene mutation. Mov Disord 2007;22:251–4.
43. Gwinn K, Devine MJ, Jin LW, et al. Clinical features, with video documentation, of the 
original familial Lewy body parkinsonism caused by α-synuclein triplication (Iowa kindred). 
Mov Disord 2011;26:2134-6.
44. Al-Chalabi A, Dürr A, Wood NW, et al. Genetic variants of the alpha-synuclein gene SNCA 
are associated with multiple system atrophy. PLoS One 2009;4(9):e7114.
45. Sailer A. First genome-wide association study in multiple system atrophy. Mov Disord 
2012;27:467.
46. Soma H, Yabe I, Takei A, et al. Heredity in multiple system atrophy. J Neurol Sci 
2006;240:107–10.
47. Ozawa T. Pathology and genetics of multiple system atrophy: an approach to determining 
genetic susceptibility spectrum. Acta Neuropathol (Berl) 2006;112:531–8.
55
48. Combarros O, Infante J, Llorca J, et al. Interleukin-1A (-889) genetic polymorphism 
increases the risk of multiple system atrophy. Mov Disord 2003;18:1385–6.
49. Furiya Y, Hirano M, Kurumatani N, et al. Alpha-1-antichymotrypsin gene polymorphism and 
susceptibility to multiple system atrophy (MSA). Brain Res Mol Brain Res 2005;138:178–81.
50. Infante J, Llorca J, Berciano J, et al. Interleukin-8, intercellular adhesion molecule-1 and 
tumour necrosis factor-alpha gene polymorphisms and the risk for multiple system atrophy. J 
Neurol Sci 2005;228:11–13.
51. Nishimura M, Kawakami H, Komure O, et al. Contribution of the interleukin-1beta gene 
polymorphism in multiple system atrophy. Mov Disord 2002;17:808–11.
52. Nishimura M, Kuno S, Kaji R, et al. Influence of a tumor necrosis factor gene polymorphism 
in Japanese patients with multiple system atrophy. Neurosci Lett 2005;374:218–21.
53. Soma H, Yabe I, Takei A, et al. Associations between multiple system atrophy and 
polymorphisms of SLC1A4, SQSTM1, and EIF4EBP1 genes. Mov Disord 2008;23:1161–7.
54. Ozawa T, Paviour D, Quinn NP, et al. The spectrum of pathological involvement of the 
striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological 
correlations. Brain 2004;127:2657–71.
55. Inoue M, Yagishita S, Ryo M et al. The distribution and dynamic density of oligodendroglial 
cytoplasmic inclusions (GCIs) in multiple system atrophy: a correlation between the density of 
GCIs and the degree of involvement of striatonigral and olivopontocerebellar systems. Acta 
Neuropathol 1997;93:585–91.
56. Ahmed Z, Asi YT, Sailer A, et al. The neuropathology, pathophysiology and genetics of 
multiple system atrophy. Neuropathol Appl Neurobiol 2012;38:4-24.
57. Wenning GK, Stefanova N, Jellinger KA, Poewe W, Schlossmacher MG. Multiple system 
atrophy: a primary oligodendrogliopathy. Ann Neurol 2008;64:239-46.
58. Wakabayashi K, Takahashi H. Cellular pathology in multiple system atrophy. 
Neuropathology 2006;26:338–45.
56
59. Yoshida M. Multiple system atrophy: alpha-synuclein and neuronal degeneration. 
Neuropathology 2007;27:484–93.
60. Ishizawa K, Komori T, Sasaki S, et al. Microglial activation parallels system degeneration in 
multiple system atrophy. J Neuropathol Exp Neurol 2004;63:43–52.
61. Schwarz J, Weis S, Kraft E, et al. Signal changes on MRI and increases in reactive 
microgliosis, astrogliosis, and iron in the putamen of two patients with multiple system atrophy. 
J Neurol Neurosurg Psychiatry 1996;60:98–101.
62. Song YJ, Lundvig DM, Huang Y, et al. p25alpha Relocalizes in oligodendroglia from myelin 
to cytoplasmic inclusions in multiple system atrophy. Am J Pathol 2007;171:1291-303.
63. Asi YT, Simpson JE, Heath PR, et al. Alpha-synuclein mRNA expression in 
oligodendrocytes in MSA. Glia 2014;62:964-70.
64. Reyes JF, Rey NL, Bousset L, Melki R, Brundin P, Angot E. Alpha-synuclein transfers from 
neurons to oligodendrocytes. Glia 2014;62:387-98.
65. Watts JC, Giles K, Oehler A, et al. Transmission of multiple system atrophy prions to 
transgenic mice. Proc Natl Acad Sci USA 2013;110:19555-60.
66. Wenning GK, Geser F, Krismer F, et al. The natural history of multiple system atrophy: a 
prospective European cohort study. Lancet Neurol 2013;12:264-74.
67. Klockgether T, Lüdtke R, Kramer B, et al. The natural history of degenerative ataxia: a 
retrospective study in 466 patients. Brain 1998;121:589-600.
68. Petrovic IN, Ling H, Asi Y, et al. Multiple system atrophy-parkinsonism with slow 
progression and prolonged survival: a diagnostic catch. Mov Disord 2012;27:1186-90.
69. Fanciulli A, Strano S, Colosimo C, Caltagirone C, Spalletta G, Pontieri FE. The potential 
prognostic role of cardiovascular autonomic failure in α-synucleinopathies. Eur J Neurol 
2013;20:231-5. 
70. Figueroa JJ, Singer W, Parsaik A, et al. Multiple system atrophy: prognostic indicators of 
survival. Mov Disord 2014;29:1151-7.
57
71. Brooks DJ, Seppi K. Proposed neuroimaging criteria for the diagnosis of multiple system 
atrophy. Mov Disord 2009;24:949-64.
72. Antonini A, Leenders KL, Vontobel P, et al. Complementary PET studies of striatal neuronal 
function in the differential diagnosis between multiple system atrophy and Parkinson’s disease. 
Brain 1997;120:2187–95.
73. Eckert T, Barnes A, Dhawan V, et al. FDG PET in the differential diagnosis of parkinsonian 
disorders. Neuroimage 2005;26:912–21.
74. Braune S, Reinhardt M, Schnitzer R, et al. Cardiac uptake of [123I] MIBG separates 
Parkinson’s disease from multiple system atrophy. Neurology 1999;53:1020–5.
75. Braune S. The role of cardiac metaiodobenzylguanidine uptake in the differential diagnosis 
of parkinsonian syndromes. Clin Auton Res 2001;11:351–5.
76. Courbon F, Brefel-Courbon C, Thalamas C, et al. Cardiac MIBG scintigraphy is a sensitive 
tool for detecting cardiac sympathetic denervation in Parkinson’s disease. Mov Disord 
2003;18(8):890–7.
77. Goldstein DS, Holmes C, Cannon RO 3rd, et al. Sympathetic cardioneuropathy in 
dysautonomias. N Engl J Med 1997;336(10):696–702.
78. Goldstein DS. Sympathetic neuroimaging. Handb Clin Neurol 2013;117:365-70.
79. Kimber J, Mathias CJ, Lees AJ, et al. Physiological, pharmacological and neurohormonal 
assessment of autonomic function in progressive supranuclear palsy. Brain 2000;123:1422-30.
80. Kimber JR, Watson L, Mathias CJ. Distinction of idiopathic Parkinson’s disease from 
multiple-system atrophy by stimulation of growth-hormone release with clonidine. Lancet 
1997;349:1877-81.
81. Beck RO, Betts CD, Fowler CJ. Genitourinary dysfunction in multiple system atrophy: 
clinical features and treatment in 62 cases. J Urol 1994;151:1336-41.
82. Gilman S, Koeppe RA, Chervin RD, et al. REM sleep behavior disorder is related to striatal 
monoaminergic deficit in MSA. Neurology 2003;61:29–34.
58
83. Benarroch EE, Schmeichel AM, Sandroni P, et al. Involvement of vagal autonomic nuclei in 
multiple system atrophy and Lewy body disease. Neurology 2006;66:378–83.
84. Benarroch EE. Brainstem in multiple system atrophy: clinicopathological correlations. Cell 
Mol Neurobiol 2003;23:519–26.
85. Benarroch EE, Schmeichel AM, Low PA, et al. Involvement of medullary serotonergic 
groups in multiple system atrophy. Ann Neurol 2004;55:418–22.
86. Papp MI, Lantos PL. The distribution of oligodendroglial inclusions in multiple system 
atrophy and its relevance to clinical symptomatology. Brain 1994;117(2):235–43.
87. Schmeichel AM, Buchhalter LC, Low PA, et al. Mesopontine cholinergic neuron 
involvement in Lewy body dementia and multiple system atrophy. Neurology 2008;70:368–73.
88. Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension: a 
clinical-pathologic study. Arch Neurol 1960;2:511–27.
89. Benarroch EE, Schmeichel AM, Sandroni P, et al. Involvement of hypocretin neurons in 
multiple system atrophy. Acta Neuropathol 2007;113:75–80.
90. Nishie M, Mori F, Yoshimoto M, et al. A quantitative investigation of neuronal cytoplasmic 
and intranuclear inclusions in the pontine and inferior olivary nuclei in multiple system atrophy. 
Neuropathol Appl Neurobiol 2004;30:546–54.
91. Daniel S. The neuropathology and neurochemistry of multiple system atrophy. In: Mathias 
CJ , Bartko JJ , eds. Autonomic failure. Oxford: Oxford University Press 1999;321–8.
92. Sone M, Yoshida M, Hashizume Y, et al. Alpha-Synuclein-immunoreactive structure 
formation is enhanced in sympathetic ganglia of patients with multiple system atrophy. Acta 
Neuropathol (Berl) 2005;110:19–26.
93. Konno H, Yamamoto T, Iwasaki Y, et al. Shy-Drager syndrome and amyotrophic lateral 
sclerosis. Cytoarchitectonic and morphometric studies of sacral autonomic neurons. J Neurol Sci 
1986;73:193–204.
59
94. Ozawa T. Morphological substrate of autonomic failure and neurohormonal dysfunction in 
multiple system atrophy: impact on determining phenotype spectrum. Acta Neuropathol 
2007;114:201–11.
95. Yamamoto T, Sakakibara R, Uchiyama T, et al. When is Onuf’s nucleus involved in multiple 
system atrophy? A sphincter electromyography study. J Neurol Neurosurg Psychiatry 
2005;76:1645–8.
96. Kelso SR, Perlmutter MN, Boulant JA. Thermosensitive single-unit activity of in vitro 
hypothalamic slices. Am J Physiol. 1982;242:77–84.
97. Pfeiffer RF, Bodis-Wollner I. Parkinsons Disease and Nonmotor Dysfunction. Humana 
Press, Totowa, NY. 2013.
98. Smith JE, Jansen AS, Gilbey MP, Loewy AD. CNS cell groups projecting to sympathetic 
outflow of tail artery: neural circuits involved in heat loss in the rat. Brain Res. 1998;786:153–
64.
99. Koga S, Aoki N, Uitti RJ, et al. When DLB, PD, and PSP masquerade as MSA: an autopsy 
study of 134 patients. Neurology 2015;85(5):404-12.
100. Chung EJ, Lee WY, Yoon WT, Kim BJ, Lee GH. MIBG scintigraphy for differentiating 
Parkinson's disease with autonomic dysfunction from Parkinsonism-predominant multiple 
system atrophy. Mov Disord. 2009;24(11):1650-5. 
101. Jost WH, Tredici Del K, Landvogt C, Braune S. Importance of 123I-
metaiodobenzylguanidin (MIBG) scintigraphy/SPECT for diagnosis and deferential diagnostics 
of Parkinson syndromes. Neurodegener Dis 2010;7:341-7.
102. Kimpinski K, Iodice V, Burton DD, Camilleri M, Mullan BP, Lipp A, Sandroni P, Gehrking 
TL, Sletten DM, Ahlskog JE, Fealey RD, Singer W, Low PA. The role of autonomic testing in 
the differentiation of Parkinson's disease from multiple system atrophy. J Neurol Sci 2012;317(1-
2):92-6.
103. Goldstein DS. Dysautonomia in Parkinson's disease: neurocardiological abnormalities. 
Compr Physiol 2014;4(2):805–826.
60
104. Goldstein DS. Orthostatic hypotension as an early finding in Parkinson disease. Clin Auton 
Res 2006;16:46–64.
105. Kovacs GG, Gelpi E, Lehotzky A, et al. The brain-specific protein TPPP/ p25 in 
pathological protein deposits of neurodegenerative diseases. Acta Neuropathol 2007;113:153–61.
106. Riley DE, Chelimsky TC. Autonomic nervous system testing may not distinguish multiple 
system atrophy from Parkinson’s disease. J Neurol Neurosurg Psychiatry 2003;74:56–60
107. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of the clinical diagnosis of idiopathic 
Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 
1992;55:181-4.
108. Task Force of the European Society of Cardiology and The North American Society of 
Pacing and Electrophysiology. Heart rate variability. Standards of measurement, physiological 
interpretation, and clinical use. European Heart Journal 1996;17:354–381.
109. Bilchick KC, Berger RD. Heart Rate Variability. J Cardiovasc Electrophysiol 2006;17:691-
694.
110. Fagius J, Wallin BG. Sympathetic reflex latencies and conduction velocities in normal man. 
J Neurol Sci 1980;47:433–448.
111. Fagius J, Wallin BG. Sympathetic reflex latencies and conduction velocities in patients with 
polyneuropathy. J Neurol Sci 1980;47: 449–461. 
112. Shahani BT, Halperin JJ, Boulu P, et al. Sympathetic skin response: a method of assessing 
unmyelinated axon dysfunction in peripheral neuropathies. J Neurol Neurosurg Psychiatry 
1984;47:536–542.
113. Elie B, Guiheneuc P. Sympathetic skin response: normal results in different experimental 
conditions. Electroencephalogr Clin Neurophysiol 1990;76:258–267.
114. Gutrecht JA. Sympathetic skin response. J Clin Neurophysiol 1994;11:519–524.
115. Buaune HJ, Horter C. Sympathetic skin response in diabetic neuropathy: a prospective 
clinical and neurophysiological trial on 100 patients. J Neurol Sci 1996;138(1-2):120-4.
61
116. Yokota T, Hayashi M, Hirashima F, et al. Dysautonomia with acute sensory-motor 
neuropathy. Arch Neurol 1994;51:1022– 1031.
117. Taly AB, Arunodaya GR, Rao S. Sympathetic skin response in Guillain-Barre syndrome. 
Clin Autom Res 1995;5:215–219.
118. Drory VE, Nisipeanu PF, Kroczyn AD. Tests of autonomic dysfunction in patients with 
multiple sclerosis. Acta Neurol Scand 1995;92:356–360.
119. Korpelainen JT, Tolonen U, Sotaniemi KA, et al. Suppressed sympathetic skin response in 
brain infarction. Stroke 1993;24:1389–1392.
120. Masur H, Schulte-Oversohl U, Papke K, et al. Sympathetic skin response in patients with 
amyotrophic lateral sclerosis. Funct Neurol 1995;10:131–135.
121. De Marinis M, Stocchi F, Gregori B, Accornero N. Sympathetic skin response and 
cardiovascular autonomic function tests in Parkinson's disease and multiple system atrophy with 
autonomic failure. Mov Disord. 2000;15(6):1215–1220.
122. Bordet R, Benhadjali J, Destee A, et al. Sympathetic skin response and R-R interval 
variability in multiple system atrophy and idiopathic Parkinson’s disease. Mov Disord 
1996;11:268–272.
123. Haapaniemi TH, Korpelainen JT, Tolonen U, Suominen K, Sotaniemi KA, Myllylä VV. 
Suppressed sympathetic skin response in Parkinson disease. Clin Auton Res. 2000;10(6):337-42.
124. Shahani BT, Day TJ, Cros D, Khalil N, Kneebone CS. RR interval variation and the 
sympathetic skin response in the assessment of autonomic function in peripheral neuropathy. 
Arch Neurol 1990;47(6):659-64.
125. Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of 
orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. 
Auton Neurosci 2011;161(1-2):46-8.
126. Cossu G, Melis M. The peripheral nerve involvement in Parkinson Disease: A multifaceted 
phenomenon. Parkinsonism Relat Disord 2016;25:17-20.
62
127. Rendell M, Bamisedun O. Diabetic cutaneous microangiopathy. Am J Med 1992;93(6):611-
8.
128. Trojanowski JQ, Revesz T. Proposed neuropathological criteria for the post mortem 
diagnosis of multiple system atrophy. Neuropathol Appl Neurobiol 2007;33:615–620.
129. Jellinger KA, Wenning GK. Multiple system atrophy: pathogenic mechanisms and 
biomarkers. J Neural Transm (Vienna) 2016;123(6):555-72.
130. Wenning GK, Granata R, Krismer F, et al. Orthostatic hypotension is differentially 
associated with the cerebellar versus the parkinsonian variant of multiple system atrophy: a 
comparative study. Cerebellum 2012;11(1):223-6.
131. Lipp A, Sandroni P, Low PA. Systemic postganglionic adrenergic studies do not distinguish 
Parkinson's disease from multiple system atrophy. J Neurol Sci 2009;281(1-2):15-9.
132. Taylor LJ, Harris J, Epps CD, Herr K. Psychometric evaluation of selected pain intensity 
scales for use with cognitively impaired and cognitively intact older adults. Rehabil Nurs 
2005;30(2):55-61.
133. Sun Z, Jia D, Shi Y et al. Prediction of orthostatic hypotension in multiple system atrophy 
and Parkinson disease. Sci Rep 2016;6:216-49.
63
VIII. PUBLISHING
The results of this study were successfully published in the Journal of Neural Transmission as an 
original article:
Augustis S, Saferis V, Jost WH. Autonomic disturbances including impaired hand 
thermoregulation in multiple system atrophy and Parkinson's disease. J Neural Transm (Vienna). 
2016 Dec 21; doi: 10.1007/s00702-016-1665-8.
IX. ACKNOWLEDGEMENTS
I am very thankful to Prof. Dr. Wolfang H. Jost for the assignment of this particularly interesting 
subject and the outstanding academic supervision. Furthermore, I would like to thank Prof.  
Viktoras Saferis for answering my questions regarding the statistical analysis and Ms. Tanja 
Fiesel for her kind assistance in the collection of data. 
